analyzed the blood samples of 149 NSCLC patients and found that the exosomal PD-L1 was correlated with the clinical response of patients to ICI treatment, implying that exosomal PD-L1 could be used for the evaluation of immunotherapeutic efficacy in lung cancer (110). This evidence concerns the gene CD274 and non-small cell lung carcinoma.